Resistant Pseudomonas aeruginosa Infections – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Resistant Pseudomonas aeruginosa Infections – Drugs In Development, 2024 report and make more profitable business decisions.
Pseudomonas aeruginosa has become an important cause of infection, especially in patients with compromised host defense mechanisms. It has an ability to rapidly develop resistance to multiple classes of antibiotics. It is the most common pathogen isolated from patients who have been hospitalized for more than one week. Signs and symptoms include pneumonia, fever, fatigue, itchy rash, bleeding ulcers, and headache. Risk factors include age and weakened immune system.
The Resistant Pseudomonas aeruginosa Infections drugs in development market research report provide comprehensive information on the therapeutics under development for Resistant Pseudomonas aeruginosa Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Resistant Pseudomonas aeruginosa Infections and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Resistant Pseudomonas aeruginosa Infections | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 16 molecules, with 12 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Resistant Pseudomonas aeruginosa Infections therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Resistant Pseudomonas aeruginosa Infections pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Resistant Pseudomonas aeruginosa Infections treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Armata Pharmaceuticals IncBiocidium Biopharmaceuticals Inc
BiomX Inc
Boston Pharmaceuticals Inc
Gnubiotics Sciences SA
Infex Therapeutics Ltd
Linnaeus Bioscience Inc
MetalloBio Ltd
Purdue University
Shionogi & Co Ltd
Southern Research Institute
Telum Therapeutics SL
University of Liverpool
University of Manitoba
VenatoRx Pharmaceuticals Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Resistant Pseudomonas aeruginosa Infections reports